High levels of circulating endothelial (EMV) and platelet-derived microvesicles (PMV) in the acute phase following ischemic stroke could be a biomarker of increased long-term risk of recurrent stroke, myocardial infarction or all-cause mortality.
Why this matters
Circulating microvesicles are shed into the bloodstream by different cell types in response to inflammation. For example, EMV are released by inflamed endothelial cells lining the blood vessels and are biomarker of endothelial dysfunction. It is thought that circulating microvesicles could be used to predict cardiovascular risk.
EMV levels are associated with stroke severity and lesion volume in ischemic stroke and other types of microvesicles – for example, platelet-derived and monocytic – are increased in the acute post-stroke phase.